Milestone Pharmaceuticals Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joseph G. Oliveto
- Full Time Employees
- 38
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1111 Dr. Frederik-Philips Boulevard Montreal QC Canada H4M 2X6
- IPO Date
- May 9, 2019
- CIK
- 0001408443
- Website
- milestonepharma.com
- Similar Companies
- Business
- Milestone Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to the advancement and commercialization of innovative cardiac treatments. The company’s primary investigational compound, etripamil, is a unique, powerful, and fast-acting calcium channel blocker administered as a nasal spray. Etripamil has concluded its Phase III clinical program for treating paroxysmal supraventricular tachycardia (PSVT) in adults within the United States and Canada. Following the submission of its response to a Complete Response Letter, the U.S. Food and Drug Administration has set a Prescription Drug User Fee Act (PDUFA) target action date of December 13, 2025, for etripamil (CARDAMYST™) for PSVT. Additionally, etripamil is undergoing a Phase II clinical study for managing atrial fibrillation with rapid ventricular rate, with a Phase III trial anticipated to commence in 2025. Milestone Pharmaceuticals also maintains a license and collaboration agreement with Corxel Pharmaceuticals for the development and commercialization of etripamil. The company was established in 2003 and its headquarters are located in Montréal, Canada.
Company News
Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Average Rating of “Moderate Buy” by Brokerages
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients' Daily Lives and Quality of Life Between Episodes
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound
Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript
Milestone Pharmaceuticals Q2 Earnings Call Highlights
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript
Milestone Pharmaceuticals: Here Comes The Revenue Ramp